<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750113</url>
  </required_header>
  <id_info>
    <org_study_id>12313</org_study_id>
    <secondary_id>2006-006436-22</secondary_id>
    <nct_id>NCT00750113</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.</brief_title>
  <official_title>A Multicenter Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control and Beyond: Comparison of Two Treatment Strategies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients having uncontrolled or poorly controlled hypertension are at risk of experiencing
      cardiovascular events such as myocardial infarction or stroke. To reduce this risk an
      appropriate antihypertensive therapy should allow to reach a target blood pressure of less
      than 130/80 mmHg in order to maximise cardiovascular protection.The purpose of this study is
      to evaluate the efficacy in blood pressure control when anti-hypertensive therapy is
      initiated with a combination of low dose Nifedipine GITS and Telmisartan compared to a
      regimen starting with monotherapy before adding the other drug.The primary efficacy parameter
      will be the 24 hour mean systolic Blood Pressure on Ambulatory Blood Pressure Monitoring
      (ABPM) at 16 weeks of treatment compared to baseline
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy parameter will be the 24 hour mean systolic Blood Pressure on Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>at 16 weeks of treatment compared to baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Office blood pressure, response rate (&gt; 10mmHg decrease control rate (&lt; 130/80) mean SBP, mean DBP.</measure>
    <time_frame>8, 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABPM: % patients achieving BP &lt; 125/80 mmHg morning BP increase/surge,24h mean diastolic BP,day average BP, night average BP,BP variability, pulse pressure through to peak ratio,smoothness index dipping or non dipping</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microalbuminuria in subgroup (any reduction)</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters: fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers: sRAGE (soluble receptors for advanced glycation end products) eotaxin-3, CRP (C-Reactive Protein)</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifidipine</intervention_name>
    <description>Tablets 20 Mg daily for 4 weeks then combination therapy</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Tablets 80 Mg daily for 4 weeks then combination therapy</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine/Telmisartan</intervention_name>
    <description>2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension (office systolic blood pressure &gt; 135 mmHg), untreated or poorly
             controlled but stable antihypertensive regimen for &gt;/= 4 weeks

          -  Presence of type 2 diabetes mellitus or target organ damage (echocardiographic or
             electrocardiographic left ventricular hypertrophy or microalbuminuria)

          -  Presence of a metabolic syndrome, i.e at least two of the following [(from letter (a)
             to letter(d)] in patients with organ damage or at least one of the following [from
             letter (b) to letter (d)] in patients with diabetes mellitus: (a) impaired glucose
             tolerance (fasting plasma glucose 110 -125 mg/dl) (b )raised serum triglycerides (&gt;/=
             150 mg/dl) or comitant use of statins for this indication(c) low HDL cholesterol
             (males: &lt; 40 mg/dl, females: &lt; 50 mg/dl)(d) waist circumference &gt;102 cm in men and &gt;88
             cm in women

          -  Age: 18-75 years

          -  Negative pregnancy test in females

          -  Written informed consent

        Exclusion Criteria:

          -  Concomitant treatment with AT1-antagonists e.g. losartan, eprosartan, telmisartan) or
             calcium-antagonists (e.g. amlodipine, felodipine, isradipine, nifedipine, nimodipine).

          -  Concomitant treatment with any other antihypertensive medication that cannot be safely
             withdrawn at entry (i.e taken on a stable regimen for &gt;/= 4 week) and that won't
             possibly be kept stable over the whole duration of the study.

          -  Concomitant treatment with known cytochrome P450-3A4 inhibitors (e.g cimetidine,
             anti-HIV protease inhibitors e.g. ritonavir, azole anti-mycotics eg. Ketoconazole,
             digoxin, quinidine, tacrolimus) or inducers such as anti-epileptic drugs (eg.
             phenytoin, carbamazepine and phenobarbitone) or rifampicin

          -  Concomitant treatment with potassium sparingdiuretics.

          -  Malignant, severe or labile essential hypertension, orthostatic hypotension

          -  Cardiovascular shock

          -  Evidence of secondary form of hypertension, including coarctation of the aorta,
             hyperaldosteronism, renal artery stenosis or pheochromocytoma

          -  Myocardial infarction or unstable angina within the previous 12 months

          -  Severe cardiac valve disease

          -  Severe rhythm or conduction disorder:

          -  Cerebrovascular ischaemic event (stroke, transient ischaemic attack) within the
             previous 12 months

          -  History of intra-cerebral haemorrhage or sub-arachnoid haemorrhage within the previous
             12 months

          -  Type 1 diabetes mellitus

          -  Proteinuria (determined by uristix)

          -  BMI &gt; 34

          -  Uncorrected hypokalemia or hyperkalemia, potassium outside the range 3.0 to 5.5 mmol/l

          -  Sodium depletion and/or hypovolemia

          -  Gastrointestinal disease resulting in the potential for malabsorption)

          -  Liver disease or transaminase (AST, ALT) levels &gt; 3 x the upper limit of normal range.

          -  Renal failure, creatinine &gt;2.0 mg/dl

          -  General Exclusion Criteria: any malignant disease that has required treatment within
             the last five years, dementia or psychosis, history of non-compliance, alcoholism or
             drug abuse, treatment with any other investigational drug in the 30 days prior to
             entering the study, pregnancy and lactation, known state of allergy or
             hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan, any
             surgical or medical condition which at the discretion of the investigator place the
             subject at higher risk from his/her participation in the study or are likely to
             prevent the subject from complying with the requirements of the study or completing
             the trial period, history of non compliance to medical regimens or subjects unwilling
             to comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Pozzilli</city>
        <state>Isernia</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monza</city>
        <state>Monza-Brianza</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somma Lombardo</city>
        <state>Varese</state>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Broni</city>
        <zip>27043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cinisello Balsamo</city>
        <zip>20092</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20143</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <zip>80136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <zip>80141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siracusa</city>
        <zip>96100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trieste</city>
        <zip>34149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Venezia</city>
        <zip>30122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrol</city>
        <state>A Coru침a</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gij칩n</city>
        <state>Asturias</state>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerez de la Frontera</city>
        <state>C치diz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beniganim</city>
        <state>Valencia</state>
        <zip>46830</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>M치laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>Click here and search for Bayer Product infromation provided by EMA</description>
  </link>
  <results_reference>
    <citation>Mancia G, Parati G, Bilo G, Choi J, Kilama MO, Ruilope LM; TALENT investigators. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. J Hypertens. 2011 Mar;29(3):600-9. doi: 10.1097/HJH.0b013e328342ef04. Erratum in: J Hypertens. 2011 May;29(5):1022.</citation>
    <PMID>21252701</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

